Agios Pharmaceuticals (AGIO) stock is in focus after the company signed an exclusive global licensing agreement with Oscotec for cevidoplenib, an oral SYK inhibitor targeting immune thrombocytopenia and other potential indications.

The cevidoplenib deal lands at a time when the share price is US$27.68, with a 1-day share price return of 4.41% but a 1-year total shareholder return that has fallen 18.66%. This suggests that recent momentum has picked up while longer term holders have still seen pressure.

If this kind of rare disease news has your attention, it could be a good moment to scan other healthcare-focused opportunities via our curated list of 39 healthcare AI stocks

With Agios reporting annual revenue of US$66.05 million alongside a net loss of US$422.60 million, and the stock still down 18.66% over 1 year, is the recent cevidoplenib excitement a genuine opening or is the market already pricing in future growth?

Most Popular Narrative: 32% Undervalued

Agios closed at $27.68, while the most followed narrative sees fair value at about $40.88. This is where the cevidoplenib news now meets a much bigger story.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Curious how this fair value is built? The narrative leans on rapid revenue expansion, a sharp margin reset, and a rich future earnings multiple. The exact mix might surprise you.

Result: Fair Value of $40.88 (UNDERVALUED)

However, this hinges on PYRUKYND meeting high expectations, as well as on regulatory and safety outcomes. Any setback or tighter labeling could quickly weaken the bullish case.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Price Tag Looks Stretched

The community narrative leans on a fair value of about $40.88, but the current P/S of 24.9x tells a different story. That is more than double the US Biotechs average of 10.7x and well above the peer average of 2.7x. This points to real valuation risk if expectations slip.

To see how that rich P/S could adjust if sentiment cools or fundamentals change, check the valuation breakdown via See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between opportunity and risk, this is a moment to move quickly, review the full picture, and weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop at a single stock, you risk missing other opportunities that could fit your goals even better, so give yourself options and compare widely.

• Spot potential mispricings by scanning a focused set of 47 high quality undervalued stocks that combine quality with appealing valuations.
• Lock in potential income streams by reviewing 10 dividend fortresses that pair higher yields with sturdier payout profiles.
• Sleep easier at night by checking 63 resilient stocks with low risk scores that score well on resilience and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.